Core Viewpoint - The former chairman of Taibang Biologic, Zhou Fan, accused the current chairman, Li Hui, of misleading investors and violating laws regarding the privatization and share allocation of the company [1][2][12]. Group 1: Company Background - Taibang Biologic is one of China's top ten blood product companies, focusing on the research, production, and sales of blood and biological products [3]. - The company went public on NASDAQ in 2009, becoming the only blood product company listed in the United States [3]. Group 2: Privatization and Shareholding Issues - During the privatization process, the original management team, led by Zhou Fan, was allowed to invest in the buyout to strengthen the case for bank loans, involving over a hundred employees [2][5]. - Zhou Fan claims that the current management is attempting to cancel the shares allocated to the original management team during privatization, which he argues is illegal [2][5]. - The privatization deal was completed in April 2021, with a total valuation of approximately $4.76 billion, and Zhou Fan held about 13.77% of the shares, valued at over $656 million at the time [6][4]. Group 3: Management Changes and Conflicts - Li Hui, the current chairman, has been accused by Zhou Fan of trying to usurp control of the company through share cancellation [1][12]. - A public statement from Taibang Biologic denied Zhou Fan's claims, asserting that they would pursue legal action against him for spreading false information [2][12]. - The management structure shows that Zhou Fan is still listed as chairman, while Li Hui has taken over the role, indicating potential discrepancies in the company's governance [6][7]. Group 4: Broader Context of Li Hui and Dazhong Capital - Dazhong Capital, founded in 2016, is known for its investments in various sectors, including healthcare, and has been involved in the controversial case of Luckin Coffee, which faced a financial scandal in 2020 [9][10]. - Despite the scandal, Dazhong Capital continued to invest in Luckin Coffee, eventually becoming its controlling shareholder [10][11].